ProRelix Research wins Best Full-Service Clinical Research Organisation 2026 at GHP Global Excellence Awards. Full Phase 1-4 services, global site networks, dedicated regulatory and pharmacovigilance teams, and proprietary hybrid decentralized platform for pharma and biotech sponsors.
Table of Contents
ProRelix Research Recognized as Best Full Service Clinical Research Organisation 2026 by GHP
In October 2026, ProRelix Research received formal recognition as the Best Full Service Clinical Research Organisation 2026 at the GHP Global Excellence Awards. This honor, presented by Global Health and Pharma through AI Global Media Ltd and signed by Jane Henderson, marks a clear milestone for a company that has focused on prompt, reliable, and ethical clinical trials since 2015. For sponsors evaluating partners at the final stage of selection, this independent recognition carries practical weight. It signals consistent delivery across complex, multi-country programs rather than marketing claims alone.
The GHP Global Excellence Awards evaluate organizations on measurable performance, operational standards, innovation in service delivery, and contribution to advancing healthcare. ProRelix Research earned the Best Full Service Clinical Research Organisation 2026 title after review of its end-to-end capabilities, global site network, quality systems, and track record with pharmaceutical, biotechnology, and medical device sponsors. The certificate confirms the award within the Global Excellence Awards 2026 program. For decision-makers comparing CROs, such third-party validation reduces uncertainty when budgets, timelines, and regulatory risk are high.
A Full CRO Service Model Built for Real-World Demands
ProRelix Research operates as a true full-service clinical research organisation (CRO). Sponsors work with one integrated team rather than stitching together multiple vendors. Services cover the complete clinical development path from Phase 1 through Phase 4. This includes clinical trial project management, site selection and feasibility, regulatory affairs, clinical operations and site management, vendor oversight, patient recruitment and retention, data management, biostatistics, medical writing, and pharmacovigilance.
Complete Portfolio of Clinical Research Services
ProRelix Research delivers a comprehensive portfolio designed for pharmaceutical, biotechnology, biopharma, medical device, nutraceutical, and herbal product sponsors. We deliver every service under ICH GCP principles with clear accountability.
Core clinical trial services include full project management across all phases. Dedicated project managers coordinate timelines, budgets, risk mitigation, and cross-functional communication from protocol finalization through database lock and clinical study report. Site selection and feasibility start with direct investigator outreach. Teams assess historical enrollment performance, patient availability, competing trials, and local regulatory timelines before recommending sites. This reduces later activation delays.
Clinical operations and site management cover initiation, monitoring, closeout, and ongoing site support. Vendor management ensures laboratory, imaging, and specialty service providers meet quality and timeline expectations. Patient recruitment and retention strategies combine traditional site-based methods with digital outreach and decentralized elements when appropriate.
Regulatory affairs support includes clinical trial applications, ethics committee submissions, IND and equivalent filings, and ongoing regulatory correspondence in multiple regions. Medical writing produces protocols, investigator brochures, informed consent forms, clinical study reports, and regulatory documents that meet agency standards. Clinical data management uses validated systems for electronic data capture, query resolution, and database lock. Biostatistics provides sample size calculation, statistical analysis plans, interim analyses, and final reporting.
A dedicated pharmacovigilance and regulatory team handles safety case processing, signal detection, aggregate reporting, and regulatory safety submissions. This specialized group works closely with clinical operations so safety data flows without friction into the overall trial record.
For Regulatory Submission
CRO for New Drug Clinical Trial
CRO for Repurposed Drug Clinical Trial
CRO for Biological & Biosimilar Clinical Trial
CRO for Bioequivalence Clinical Trial in Patient
CRO for Hybrid and Decentralized Clinical Trial
CRO for Personalized Medicine Clinical Trial
CRO For Stem Cell Therapy Clinical Trial
CRO for Medical Device Clinical Trial / Evaluation
CRO For 510 k, PMA & De Novo Clinical Trial
CRO For CE Marking Clinical Trial
CRO For Software As Medical Device Clinical Trial / Evaluation
CRO For In Vitro Diagnostics Clinical Evaluation
For Claims Support
CRO For Investigator Initiated Trials (IITs)
CRO for Real-World Evidence RWE Clinical Trial
CRO for Nutraceutical Clinical Trial
Global Presence and Extensive Site Networks
ProRelix Research maintains operational offices in the United States and India. The US presence supports North American sponsors and FDA-focused programs. The India office anchors South Asian operations and provides cost-effective, high-quality execution capacity. Beyond these offices, the organisation maintains active site networks across Europe and Southeast Asia. Countries and regions covered through investigator relationships include Thailand, South Africa, Denmark, Poland, Bulgaria, Australia, and additional European locations.
This combination of owned offices and curated site networks allows multi-country trials to launch with local regulatory insight and centralized oversight. Sponsors gain access to diverse patient populations while retaining single-point accountability for quality, timelines, and data integrity. The network has supported successful multi-country studies, including complex oncology programs that required coordinated activation across borders.
Therapeutic Area Expertise Across the Portfolio
ProRelix Research reflects depth across multiple therapeutic areas. Oncology remains a flagship domain. Experience covers adult and pediatric populations, solid tumors such as breast, ovarian, colorectal, liver, renal, and bone cancers, as well as hematologic malignancies including acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, and non-Hodgkin lymphoma.
Cardiovascular programs address hypertension, heart failure, coronary artery disease, and atrial fibrillation. Central nervous system work includes neurological conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, and stroke, together with psychiatric disorders and pain management studies. Medical device trials support 510(k), PMA, and De Novo pathways with full clinical and regulatory execution. Cosmetic and consumer health studies focus on safety, tolerability, efficacy, and claims substantiation under relevant regional guidelines. Nutraceutical and herbal product development follows the same disciplined clinical and regulatory framework.
This breadth means sponsors in specialized or mixed portfolios can work with one organisation rather than multiple niche providers.
Dedicated Teams for Pharma and Regulatory Needs
ProRelix Research structures its organisation with a clear focus on pharmaceutical development requirements. Dedicated regulatory affairs professionals manage submissions and agency interactions across major markets. The Atvigilx pharmacovigilance team operates as a specialized unit with processes aligned to global safety reporting standards. These groups work as integrated partners to clinical operations rather than separate silos. The result is faster response to regulatory questions, cleaner safety data packages, and reduced risk of inspection findings related to documentation gaps.
Project leadership remains accountable for overall delivery. This structure supports both large pharmaceutical companies seeking consistent global partners and emerging biotechs that need experienced guidance without excess layers.
Proprietary Platform for Hybrid and Decentralized Studies
Modern trials increasingly require flexible designs. ProRelix Research operates its own proprietary decentralized clinical trial platform, ProCTTH. This technology supports hybrid models that combine traditional site visits with remote data collection, telemedicine, home health services, and direct-to-patient approaches when scientifically appropriate.
The platform improves patient access and retention, particularly for studies involving mobility-limited populations, rare diseases, or geographic dispersion. It integrates with standard clinical systems so data quality and source documentation remain inspection-ready. Sponsors can choose fully site-based, hybrid, or more decentralized approaches based on protocol needs rather than being limited by vendor technology constraints. This capability formed part of the operational strength evaluated for the 2026 award.
Key Capabilities of ProRelix Research
| Capability Area | Description | Key Benefit for Sponsors |
|---|---|---|
| Full Phase 1 to 4 Services | Project management, operations, data, biostats, medical writing | Single accountable partner across development |
| Regulatory Affairs | Submissions, ethics, IND/CTA support across regions | Faster startup and cleaner regulatory packages |
| Pharmacovigilance | Dedicated safety team for case processing and reporting | Reliable safety oversight and compliance |
| Site Networks | USA, India, Europe, Southeast Asia, additional countries | Diverse enrollment and multi country reach |
| Decentralized Trial Platform | Proprietary hybrid and remote capabilities | Improved access, retention, and flexibility |
| Therapeutic Coverage | Oncology, cardiovascular, CNS, devices, cosmetics, nutraceuticals | Depth without needing multiple CROs |
| Quality Systems | ICH GCP-aligned processes and inspection readiness | Reduced audit risk and higher data integrity |
When sponsors reach the bottom of the evaluation funnel, the choice of clinical research organisation determines whether a program stays on timeline and budget. Recognition as Best Full Service Clinical Research Organisation 2026 provides external confirmation that ProRelix Research has met independent criteria for operational excellence, service integration, and contribution to the sector.
The combination of complete service coverage, global offices and site networks, specialized regulatory and pharmacovigilance teams, therapeutic depth, and an owned decentralized trial platform addresses the practical risks that cause most program delays. Sponsors receive one integrated partner capable of adapting to protocol needs while maintaining consistent quality standards.
Frequently Asked Questions
Phase 1 to 4 project management, site selection and feasibility, regulatory affairs, clinical operations, patient recruitment and retention, data management, biostatistics, medical writing, pharmacovigilance, and vendor management. Hybrid and decentralized options are available through the proprietary platform.
Offices are located in the United States and India. Active site networks extend across Europe and Southeast Asia, including locations such as Thailand, South Africa, Denmark, Poland, Bulgaria, and Australia, supporting multi-country trials with local insight.
Yes. The organisation operates its own proprietary decentralized clinical trial platform that enables hybrid designs combining site based and remote elements while preserving data quality and regulatory compliance.
Contact the business development team through the company website or by email. Provide basic protocol information, target regions, and timeline expectations. The team will arrange a capabilities discussion focused on feasibility, approach, and fit for the specific development need.
ProRelix Research continues to deliver prompt, reliable, and ethical clinical trials as the recognised Best Full Service Clinical Research Organisation 2026. Sponsors seeking an integrated partner with proven global reach, dedicated regulatory and safety expertise, therapeutic depth, and modern hybrid trial capabilities now have clear external validation of that strength. The next step is a direct conversation about the specific program requirements.
